# US 2001/0026800 A1 · Selective activation of a TH1 or TH2 lymphocyte regulated immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026800 A1
- Document ID: US20010026800A1
- Status: Published application
- Kind: A1
- Application number: 09/757,311
- Filed: 2001-01-08
- Published: 2001-10-04
- Earliest claimed: 2000-01-07
- Inventors: Jacob G. Michael
- Web page: https://patentgrep.com/patent/US20010026800A1

## CPC

- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/35: Allergens
- A61K 47/6921: {the form being a particulate, a powder, an adsorbate, a bead or a sphere}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K 9/5078: {with drug-free core}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The invention discloses methods for inducing a desired T helper lymphocyte regulated immune response by delivering an immunogen to a preselected region of the gastrointestinal tract of a subject. The invention finds application in the immunological and biomedical fields.

## Claims

### Claim 1

A method of inducing a type of T helper lymphocyte-regulated immune response in a subject comprising administering to said subject an immunogenic composition comprising at least one immunogen, wherein said immunogen is delivered to a preselected region of the gastrointestinal tract of said subject and induces said type of immune response, wherein said type of immune response is dependent on said region of the gastrointestinal tract.

### Claim 2 (depends on 1)

The method of claim 1, wherein said immunogen is selected from the group consisting of an allergen, a killed bacterium or a bacterial component, a killed virus or a viral component, a peptide, a protein fragment, a protein or glycoprotein, a gene, a gene fragment, a DNA, an RNA, a polysaccharide or lipopolysaccharide and combinations thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein said immunogen is selected from the group consisting of a self protein, an altered self protein or peptides or fragments associated with self proteins, wherein said subject has autoimmune disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein said immunogen is encapsulated with. a coating selected from the group consisting of an aqueous enteric coating, a timed-release coating, and a controlled-release coating, wherein said immunogenic composition is administered orally.

### Claim 5 (depends on 1)

The method of claim 1, wherein said immunogen is encapsulated with. an acrylic polymeric enteric coating and said region of the gastrointestinal tract is dependent on the composition of said enteric coating.

### Claim 6 (depends on 1)

The method of claim 1, wherein said immunogen is encapsulated with both an enteric coating and an aqueous timed-release coating or controlled-release coating, wherein said region of the gastrointestinal tract is dependent on the composition of said timed-release coating or controlled-release coating.

### Claim 7 (depends on 5)

The method of claim 5, wherein said immunogenic composition further comprises an adjuvant.

### Claim 8 (depends on 5)

The method of claim 5, wherein said immunogenic composition further comprises a mucoadhesive agent for adhering the immunogen to the gastrointestinal tract wall.

### Claim 9 (depends on 5)

The method of claim 5, wherein said immunogen is microencapsulated on particles of a pharmaceutically inert material.

### Claim 10 (depends on 9)

The method of claim 9, wherein said immunogen is microencapsulated on said inert material along with a stabilizing sugar and a binding agent to bind the immunogen to said inert material.

### Claim 11 (depends on 5)

The method of claim 5, wherein said enteric coating dissolves in said region of the gastrointestinal tract, whereby said immunogen is released to said region of the gastrointestinal tract.

### Claim 12 (depends on 11)

The method of claim 11, wherein said immunogen is an allergen.

### Claim 13 (depends on 11)

The method of claim 11, wherein said enteric coating is selected from the group consisting of a trans-intestinal release coating and a duodenal-release coating, and said immune response is selected from the group consisting of a T helper 1 cell regulated immune response and a T helper 2 cell regulated immune response.

### Claim 14 (depends on 13)

The method of claim 13, wherein said enteric coating is Eudragit® FS30D, wherein said region of the gastrointestinal tract is jejunum, ileum, colon, or rectum.

### Claim 15 (depends on 14)

The method of claim 14, wherein said immune response is a predominantly T helper 1 cell regulated immune response.

### Claim 16 (depends on 13)

The method of claim 13, wherein said enteric coating is Eudragit® L30D, wherein said region of the gastrointestinal tract is duodenum.

### Claim 17 (depends on 16)

The method of claim 16, wherein said immune response is a predominantly T helper 2 cell regulated immune response.

### Claim 18

A method of inducing multiple types of immune responses in a subject comprising administering to said subject a plurality of immunogenic compositions each composition comprising at least one immunogen, wherein the immunogen in each said immunogenic composition is delivered to a different preselected region of the gastrointestinal tract of said subject and induces a different type of immune response, wherein said type of immune response is dependent on said region of the gastrointestinal tract.

### Claim 19 (depends on 18)

The method of claim 18, wherein said immunogen is encapsulated with a coating selected from the group consisting of an aqueous enteric coating, a timed-release coating, and a controlled-release coating, wherein said immunogenic compositions are administered orally.

### Claim 20 (depends on 18)

The method of claim 18, wherein said immunogen is encapsulated with an acrylic polymeric enteric coating, wherein said immunogenic compositions are administered orally, and said region of the gastrointestinal tract is dependent on the composition of said enteric coating.

### Claim 21 (depends on 20)

The method of claim 20, wherein said enteric coating dissolves in said gastrointestinal tract, whereby said immunogen is released to said gastrointestinal tract.

### Claim 22 (depends on 21)

The method of claim 21, wherein said enteric coating is selected from the group consisting of a trans-intestinal release coating and a duodenal-release coating, and said immune response is selected from the group consisting of a T helper 1 cell regulated immune response and a T helper 2 cell regulated immune response.

### Claim 23 (depends on 22)

The method of claim 22, wherein said trans-intestinal release coating is Eudragit® FS30D and said duodenal-release coating is Eudragit® L30D.

### Claim 24

A method of orally inducing immune responses in a subject with an immunogen that is acid labile at any pH below 7.0, comprising administering to said subject said immunogen that is encapsulated with an enteric coating, wherein said enteric coating releases said immunogen only at a region of the gastrointestinal tract in which said immunogen is stable.

### Claim 25 (depends on 24)

The method of claim 24, wherein said enteric coating is Eudragit® FS30D.

### Claim 26 (depends on 24)

The method of claim 24, wherein said region of the gastrointestinal tract is jejunum, ileum, colon, or rectum.

### Claim 27 (depends on 24)

The method of claim 24, wherein said immunogen is an influenza viral antigen.
